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Bacterial meningitis requires early treatment with aggressive use of potent antimi-
crobials, otherwise the outcome almost ends fatally. This prospective study includes 
1442 cases of pyogenic meningitis which have been admitted to the Teaching Fever 
Hospital/ Neurosurgical Unit in Baghdad over a period of 15 years (1991 – 2006). The 
diagnostic yield by isolation and culturing of the causative microbes from the CSF 
was positive for 212 cases (14.7%). The antibiotics used in the treatment of the cases 
were different and in many instances not practiced according to the standard sched-
ule, but to the availability of the antimicrobial agents during the years of blockade on 
Iraq between 1990 and 2003. The number of cases was 212 (113 male and 99 female); 
of these, 170 cases were community acquired and 42 cases were hospital- acquired 
meningitis in the neurosurgical unit. The age of treated patients ranged between 
1-67 years with no significant difference between gender and ages. The pattern of 
bacteria species isolated from CSF were S. pneumoniae (104), N. meningitis (44), H. 
influenzae (22), E.coli (14), Pseudomonas spp. (8), Proteos (8), S. aureus (2), Salmonella 
(2) and eight other isolates . The antibiotics used were penicillin, ampicillin, chlorem-
phenicol, cefotaxim, ceftriaxone, rifampicin, gentamycin, tobramycin, and vancomy-
cin singly or in various combinations. The treatment of cases ranged between 1-3 
weeks according to type of the microorganism. The case fatality rate (CFR) was 12.2% 
for meningitis caused by S. pneumoniae, 5.3% for N. meningitis and 4.5% for H. influen-
zae. The CFR for nosocomial meningitis was 28.6%; it was highest among salmonella 
and S. aureus cases. It can be concluded that the empirical antibiotic regimens should 
be evaluated each time to escape the development of antimicrobial resistance; also, 
longer courses of antibiotic therapy might not be needed.
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Introduction
Bacterial meningitis is a life-threatening illness that results from 
bacterial infection of the meninges (1-4 ). Beyond the neonatal 
period, the 3 most common organisms that cause acute bacte-
rial meningitis are Streptococcus pneumoniae, Neisseria menin-
gitides, and Haemophilus influenzae type b (Hib)(3-6) . Although 
S pneumoniae was the leading cause of community-acquired 
bacterial meningitis in the United States, but since the intro-
duction of the conjugate pneumococcal vaccine in 2000, the 
rate of pneumococcal meningitis in the USA has declined 59% 
(1, 5-7 ). The emergence of penicillin-resistant S pneumoniae 
has resulted in new challenges in the treatment of bacterial 
meningitis (1, 2). Antibiotics should be administered as soon 
as possible once bacterial meningitis is established in patients 
(8-13 ). Initial antibiotic selection should provide coverage for 
the 3 common pathogens: S pneumoniae, N meningitides, and 
H influenza (1-5, 14).
The combination of vancomycin with either ceftriaxone or ce-
fotaxime is recommended for those with suspected bacterial 
meningitis, based upon susceptibilities of isolated pathogens 
if possible (1, 2, 12, 14 ).This combination provides adequate 
coverage for most penicillin-resistant pneumococci and beta-
lactamase resistant Hib (1, 2, 13). However, Ceftazidime has 
poor activity against pneumococci and should not be substi-
tuted for cefotaxime or ceftriaxone. 
Traditionally, initial antimicrobial treatment consists of ampi-
cillin and an amino glycoside combination (ampicillin and ce-
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fotaxime also appropriate), and if S. pneumoniae infection is 
suspected, vancomycin should be added. Initial empiric ther-
apy for late-onset disease in preterm infants should include 
an antistaphylococcal agent and ceftazidime, amikacin, or me-
ropenem (carbamapenems group). Several third-generation 
cephalosporins achieve good CSF levels and have emerged as 
effective agents against gram-negative infections. There has 
been considerable good experience with use of cefotaxime 
and ceftriaxone (1, 3, 5). Also, aminoglycosides; gentamicin and 
tobramycin have proven effective when combined with a beta-
lactam antibiotic for the treatment of pediatric cases of men-
ingitis caused by bacteria such as group B streptococci and 
susceptible enterococci. Routine intrathecal administration of 
aminoglycosides has no additional benefit in this capacity (1).
Hospital-acquired meningitis caused by S. aureus, anaerobic 
bacteria and P. aeruginosa may require other antimicrobials, 
such as methicillin, oxacillin, vancomycin, or a combination of 
ceftazidime with amino glycoside for P. aeruginosa . The etio-
logic agent and clinical course will determine the duration of 
treatment, the guidelines are not standardized and therefore 
duration of therapy may need to be individualized on the basis 
of the patient’s clinical response. 
Vancomycin and rifampin should be considered for infection 
with S. pneumoniae; chloramphenicol is recommended for pa-
tients with meningococcal meningitis who have significant hy-
persensitivity to beta-lactam antimicrobial agents (1-4, 13-17 ). 
Examination of the CSF at the end of treatment has not proven 
helpful in predicting relapses of meningitis (1, 18-20). The study 
has been done during the period of severe blockade on Iraq, 
therefore susceptibility test of isolates in vitro was not always 
available and the study has more concentrated on the bacterial 
etiology and outcome of treated bacterial meningitis. 
Patients and Methods
All cases of pyogenic meningitis over a period of 15 years (1991 
– 2006) admitted to the Teaching Fever Hospital - Neurosurgi-
cal Unit in Baghdad were studied. The cases were referred from 
private physicians, other hospitals for diagnosis and treatment 
or they were admitted directly to the Neurosurgical Unit of the 
Teaching Hospital for cranial surgery. Thorough clinical and 
neurological examination was done for each patient besides 
the following investigations are routinely done: Hematocrit 
values, CSF examination for chemistry and microbial detec-
tion by Gram stain and CSF culture on aerobic and anaerobic 
culture media. Brain visualization by MRI and CT scan imaging 
were done when indicated for some patients but not routinely 
for all cases. On admission, and after CSF specimen taken from 
patients, an intravenous line is set up and empirical antibiot-
ics treatment is starting depending on the availability of the 
antibiotic type in hospital. Ampicillin alone or in combination 
with Chloramphenicol or gentamycin is given. Cases of noso-
comial infection were mostly given vancomycin, cefotaxim and 
ceftriaxone singly or in combination. Rifampicin or tobramycin 
were added for some cases of Pseudomonus and Proteus men-
ingitis. The antibiotic might be changed after the CSF results to 
another more potent one (if it is available) or it was continued 
to complete the recommended course. 
Results
 This study includes only patients diagnosed by culture iso-
lation of bacteria from their CSF specimens. These were 212 
cases (170 community acquired and 42 hospital acquired). 
There were 113 males and 99 females; their age ranged be-
tween 1-67 years (means 35 years for males and 32 years for 
females) (Table 1). The hospital acquired bacteria species were 
14 E.coli, 8 Pseudomonas spp., 8 Proteus spp., and each 2 S. aureus 
and Salmonella spp. Eight other isolates were included; Acineto-
bactor spp., Streptococcus viridians, Listeria spp., Enterococci spp. 
and Mimma polymorpha (Table 2).
The community acquired cases of meningitis were 170 cases, 
represented by 104 cases of pneumococcal meningitis, 44 cas-
es of N. meningitides and 22 of H.influenzae b (Hib) (Table 3). 
There was no significant difference between the different com-
binations of antibiotics on the outcome of the CFR of the differ-
ent cases of the community acquired meningitis, no difference 
between them according to the gender. There was significant 
difference (p <0.001) in the CFR between the hospital- acquired 
and the community acquired types of meningitis.
TABLE 1. Gender and age of cases of bacterial meningitis (No. 212 cases)
Gender No. of cases Mean age (years)
Males 113 35 (2-67)
Females 99 32 (1-58)
Total 212
TABLE 2. Cases of Nosocomial Meningitis (No 42 cases)







Cefotaxim + Ampicillin 8 12.5
Pseudomonas
Cefotaxim + Gentamycin 4 25
Cefotaxim + Tobramycin 4 25
Proteos Cefotaxim + Rifampicin 8 25
S.aureus
Vancomycin 1 50






Others Ceftriaxone 8 25
Total 42 28.6
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alone (14, 15) . Cefotaxime and ceftriaxone also provide good 
activity against most penicillin-resistant S. pneumoniae (16). 
This study has used treatment with cefotaxim and ceftriaxone 
for most hospital-acquired meningitis cases, and only used for 
minority of the community-acquired cases (12% of S. pneu-
moniae and Hib). Both vancomycin and cefotaxime should be 
administered in patients with S. pneumoniae meningitis before 
antibiotic susceptibility results are available(1, 3). The length of 
antimicrobial therapy courses is not fixed; an analysis of ran-
domized controlled trials has evaluated the efficacy and safety 
of short-course antibiotic therapy for bacterial meningitis (6).  
This study has used long and short courses of therapy which 
has involved children (aged 3 week to 16 year) . No difference 
was demonstrated in the end of therapy in relation to clini-
cal success, long-term neurological complications, long-term 
hearing impairment, total adverse events, and secondary nos-
ocomial infections between short-course (4-7 days) and long-
course (7-14 days) treatment with intravenous ceftriaxone. The 
American Academy of Pediatrics does not endorse a shorter 
course of therapy than 5-7 days for meningococcus, 10 days 
for H influenzae, and 14 days for S pneumonia (6). Although the 
available evidence is limited, some studies show no difference 
between short-course and long-course antibiotics for bacterial 
meningitis in children (7 ).
According our experience we found antibiotic treatment of 
purulent meningitis caused by Hib, N. meningitides, or S. pneu-
moniae can be safely discontinued in children who are stable 
by day five. However, this approach should not be considered 
the standard of care in all meningitis cases (8). Our guidlines 
in the Fever hospital in Baghdad for treatment of community-
acquired meningitis is seven days for N. meningitides, ten days 
for Hib and no less than two weeks hospital treatment for S. 
pneumoniae. For hospital- acquired meningitis cases, the treat-
ment is continued for three weeks. We treated our patients 
during the critical time of blockade on Iraq after the dessert 
storm in 1991, with great shortage in the antibiotics and other 
medical supplies for Iraq and therefore the choice of the best 
antimicrobial coverage was lacking.
Conclusions 
The empirical treatment for bacterial meningitis is still the rule 
before bacterial isolation and susceptibility tests is available. 
Different antibiotics carefully chosen and given singly or in 
combination can offer optimum results. The length of treat-
ment is still controversial, however, shorter courses can be 
enough for cure and being cost benefit effective. Nosocomial 
meningitis needs careful awareness and choice of antibiotics 
to cover the hospital acquired resistance pathogens for longer 
periods than the community-acquired meningitis.
TABLE 3.  Types of microorganisms and anti microbial treatment in the 






































Prompt administration of antibiotics to a patient with suspect-
ed bacterial meningitis is essential for successful cure especial-
ly without complication. We used ampicillin “single or in com-
bination” as empirical drug for treatment of nearly 70% of the 
community-acquired bacterial meningitis. Ampicillin provides 
good coverage for gram-positive cocci, including group B strep-
tococci, enterococci, L monocytogenes, some strains of E coli, and 
Hib. Ampicillin also achieves adequate levels in cerebrospinal 
fluid (CSF)(1, 3, 21-26). Aminoglycosides (amikacin, gentamicin, 
tobramycin) have good activity against most gram-negative 
bacilli, including P. aeruginosa and S. marcescens. However, 
aminoglycosides achieve only marginal levels in both CSF and 
ventricular fluid, even when the meninges are inflamed (17, 22). 
Cephalosporins are empirically given for undiagnosed cases of 
meningitis elsewhere as recommended in many references (1-
4, 18 ). We used cefotaxim singly for treatment of six cases of 
E.coli meningitis and one case of Salmonella meningitis and 
the CFR was higher than in its combination with ampicillin 
(16.7% vs. 12.5% respectively). Cephalosporin’s have no any ac-
tivity against L. monocytogenes and enterococci and, therefore, 
should not be used as a single agent for initial treatment espe-
cially among hospital-acquired cases. If the bacterial isolate is 
susceptible in vitro to ampicillin with a low minimum inhibitory 
concentration (MIC), then ampicillin may be continued used 
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